24 November 2020 in Food & Function
Objective: The purpose of the systematic review and meta-analysis was to determine if low-ratio n-6/n-3 long-chain polyunsaturated fatty acid (PUFA) supplementation affects serum inflammation markers based on the current studies. Methods: PubMed, Embase and The Cochrane library databases were systematically searched to find randomized controlled trials (RCTs) on the effect of low-ratio n-6/n-3 PUFA intervention on inflammation markers up to July 2020. Data were pooled using standardized mean difference (SMD) and 95% confidence intervals (95% CI), with P value ≦ 0.05 as statistical significance. Results: Thirty-one RCTs were included in the meta-analysis. The analysis indicated that increasing low-ratio n-6/n-3 PUFA supplementation decreased the level of tumor necrosis factor-α (TNF-α) (SMD = −0.270; 95% CI: −0.433, −0.106; P = 0.001) and interleukin 6 (IL-6) (SMD = −0.153; 95% CI: −0.260, −0.045; P = 0.005). There were no significant effects on C-reactive protein (CRP) (SMD = −0.027; 95% CI: −0.189: 0.135; P = 0.741). Subgroup analysis indicated that there was a significant reduction in TNF-α serum concentration in subjects from Asia (SMD: −0.367; 95% CI: −0.579, −0.155; P = 0.001) and in subjects with diseases (SMD: −0.281; 95% CI: −0.436, −0.127; P < 0.001). In the subgroup of the n-6/n-3 ratio ≦5, low-ratio n-6/n-3 PUFA supplementation could decrease the level of TNF-α (SMD: −0.335; 95% CI: −0.552, −0.119; P = 0.002). Serum IL-6 decreased significantly in patients from the Europe subgroup (SMD: −0.451; 95% CI: −0.688, −0.214; P < 0.001), but not in Asia (SMD: −0.034; 95% CI: −0.226, 0.157; P = 0.724), North America (SMD: −0.115; 95% CI: −0.274, 0.044; P = 0.157) and Oceania (SMD: 0.142; 95% CI: −0.557, 0.842; P = 0.690). Conclusion: Low-ratio n-6/n-3 PUFA supplementation could decrease significantly the concentration of serum TNF-α and IL-6, but not decrease CRP concentration.
10 May 2019 in Food & Function
Objective: The aim of this meta-analysis was to investigate the effect of increasing dietary low-ratio n-6/n-3 polyunsaturated fatty acid (PUFA) intake on blood glucose and other related indicators. Methods: We systematically searched randomized controlled trials of low-ratio n-6/n-3 PUFA intervention on PubMed, Embase, Cochrane library and related references up to August 2018. The change values were calculated as the weighted mean difference (WMD) by using a random-effect model. Results: Eleven randomized controlled trials were included. No significant effect of dietary low-ratio n-6/n-3 PUFA supplementation was observed on fasting blood glucose (WMD: 0.057 mmol L−1; 95% CI: −0.090 to 0.204 mmol L−1), insulin (WMD: −0.757 mIU L−1; 95% CI: −2.419 to 0.904 mIU L−1), insulin resistance index (WMD: −0.201; 95% CI: −0.566 to 0.165), and glycosylated hemoglobin (WMD: −0.063%; 95% CI: −0.061 to 0.186%). Subgroup analysis showed that the effect of low-ratio n-6/n-3 PUFA on the reduction of the plasma insulin level in North America (WMD: −3.473 mIU L−1; 95% CI: −5.760 to −1.185 mIU L−1) was more obvious than that in Asian countries (WMD: −0.797 mIU L−1; 95% CI: −2.497 to 0.902 mIU L−1) and European countries (WMD: −0.063 mIU L−1; 95% CI: −0.061 to 0.186 mIU L−1). In the subgroup of diabetic subjects, low-ratio n-6/n-3 PUFA supplementation can decrease the plasma insulin level (WMD: −3.010 mIU L−1; 95% CI: −5.371 to −0.648 mIU L−1) and insulin resistance index (WMD: −0.460; 95% CI: −0.908 to −0.012). When the intervention period was longer than 8 weeks, low-ratio n-6/n-3 PUFA supplementation could also decrease the plasma insulin level (WMD: −2.782 mIU L−1; 95% CI: −4.946 to −0.618 mIU L−1). No significant publication bias was observed for all blood glucose and other related indicators as suggested by Begg's test and Egger's test. Conclusion: Our meta-analysis found that low-ratio n-6/n-3 PUFA supplementation could improve the glucose metabolism by reducing the insulin and insulin resistance in the diabetic patients. Low-ratio n-6/n-3 PUFA supplementation could reduce the plasma insulin level when the supplementation duration was longer than 8 weeks.